Voices
Capucine Baldini
Capucine Baldini/LinkedIn

Capucine Baldini: Phase 1/2 Duravelo-1 Study in Advanced Solid Tumors – Key Results

Capucine Baldini, Medical Oncologist at Gustave Roussy, shared a post on LinkedIn:

“Check out the results of the phase 1/2 study Duravelo-1 evaluating Zelenectide Pevedotin (nectine-4 bicyclic conjugated peptide) in advanced solid tumors

  •  Favorable safety profile compared to MMAE ADC
  •  Shorter half-life
  •  Promising preliminary efficacy: ORR of 24% and CBR of 48% in the efficacy evaluable patients
  •  No clear impact of nectine-4 expression on efficacy.”

Title: First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

Authors: Capucine Baldini, Loic Verlingue, Vincent Goldschmidt, Bernard Doger de Spéville, Julia Lostes, Antoine Italiano, Sophie Cousin, Gerald S. Falchook, Andrea Necchi, Oscar Reig Torras, Elisa Fontana, Louise Carter, Jordi Rodon Ahnert, Jason R. Brown, Leslie R. DeMars, Kate Josephs, Amy Dickson, Cong Xu, Justin Bader, Carly Campbell, Rajiv Sharma, Meredith McKean

Read the Full Article.

Capucine Baldini: Phase 1/2 Duravelo-1 Study in Advanced Solid Tumors - Key Results

More from Capucine Baldini.

Amy Dickson Andrea Necchi Antoine Italiano Bernard Doger De-Speville cancer Capucine Baldini Carly Campbell Cong Xu Elisa Fontana Gerald S. Falchook Jason R. Brown Jordi Rodon Ahnert Julia Lostes Justin Bader Kate Josephs Leslie R. DeMars Loic Verlingue Louise Carter Meredith McKean OncoDaily Oncology Oscar Reig Torras Rajiv Sharma Sophie Cousin Vincent Goldschmidt